Tigo Energy Expands Predict+ for Utility Analytics as Platform Approaches 10X Annual Growth
Predict+ platform surpasses 140,000 meters under management globally, expands advanced feature set, and brings machine learning-powered energy consumption and production prediction to utilities in Europe and North America.
Tigo Energy, Inc. (NASDAQ: TYGO) (“Tigo”), a leading provider of intelligent solar and energy software solutions, today announced a set of powerful enhancements to the Predict+ platform that gives utilities deep insight into grid demand, renewable generation, and energy market dynamics. Designed to enhance the accuracy, scalability, and robustness of energy forecasting with up to 97.5% accuracy through machine learning and artificial intelligence, the platform leverages smart meter consumption data to predict precise grid production and consumption forecasts. Predict+ helps energy providers streamline operations, reduce volatility, and maximize performance. Since the first quarter of 2024, the Predict+ platform has grown from 15,000 to 140,000 meters under management and covers a total of 600 GWh of energy today.
Predict+ empowers utility operators to adapt to real-world demand challenges when balancing renewable and baseload generation sources, particularly during extreme weather events and market disruptions. The platform delivers actionable intelligence that improves load forecasting accuracy while reducing manual workload, with data intervals ranging from yearly, monthly, daily, and down to by-the-minute data resolution. Predict+ includes the following primary functional domains:
- Market Insights: an accurate view of the near-term energy market trends combined with customer-internal data in an easy to consume, customizable dashboard
- Customer Insights: a combination of market and cost data used to evaluate the financial impact of expanding into new markets or acquiring high-value customers
- Profit Analysis: predicts and documents actual revenues from end-customers with integrated billing and invoicing functions taking existing processes from days, down to minutes.
- Regulatory Support: automatically generates forecast plans and securely transmits the plans to regulatory agencies in select regions
“The Predict+ platform doesn't only allow our customers to lower operating costs and streamline workflows, it actually drives higher returns on investment and more resilient, intelligent renewable energy infrastructure,” said Zvi Alon, chief executive officer at Tigo Energy. “As Predict+ expands into Europe and North America, we are bringing machine learning to energy analytics and predictions to a new standard for energy forecasting. As energy generation becomes more diverse and markets become increasingly dynamic, Predict+ offers a competitive edge by bringing grid stability and true foresight to utility operators.”
Predict+ has the ability to quickly recalibrate demand and load forecasts in response to external disruptions—such as COVID-19 and extreme weather events—which gives grid operators a distinct competitive edge. Existing customers continue to validate the platform’s real-world value by expanding their usage, adding modules, and scaling capacity. Predict+ stands apart from traditional forecasting methods by leveraging advanced algorithms that reduce volatility, improve accuracy, and streamline operations, often outperforming legacy approaches like spreadsheets by up to 11%, with approximately 3% deviation from actual. By consistently delivering higher accuracy with reduced manual intervention, Predict+ has become a trusted solution for energy providers looking to optimize grid performance through forecasting.
To learn more about Predict+ or participate in a platform demonstration, contact the Tigo team here and select “Predict+ info/demo” in the subject menu.
About Tigo Energy
Founded in 2007, Tigo Energy, Inc. (Nasdaq: TYGO) is a worldwide leader in the development and provider of smart hardware and software solutions that enhance safety, increase energy yield, and lower operating costs of residential, commercial, and utility-scale solar systems. Tigo combines its Flex MLPE (Module Level Power Electronics) and solar optimizer technology with intelligent, cloud-based software capabilities for advanced energy monitoring and control. Tigo MLPE products maximize performance, enable real-time energy monitoring, and provide code-required rapid shutdown at the module level. The company also develops and manufactures products such as inverters and battery storage systems for the residential solar-plus-storage market. For more information, please visit www.tigoenergy.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250210484457/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Swiss-Based Debiopharm Seeks to Boost Innovation in Japanese Cancer Research Through the New "Ideal Japan” Program18.11.2025 08:00:00 CET | Press release
After 20 years of the prestigious JCA (Japanese Cancer Association) Mauvernay Award in Japan, Debiopharm is now transitioning its longstanding support for Japanese research to the new IDEAL Japan initiativeThe “Innovation Debiopharm Academia Life Science” (IDEAL) program is designed to financially and scientifically support academic research with the goal of accelerating the translation of innovation into novel therapies for patientsThe first IDEAL Japan agreement was signed with the National Cancer Center Japan Research Institute Laboratory of Genome Stability Maintenance to advance research in early-stage colon cancer Debiopharm (www.debiopharm.com), a Swiss biopharmaceutical company aiming to cure cancer and infectious diseases, is pleased to announce today the launch of the new IDEAL Japan initiative. This program was initiated to provide financial support to Japanese academic researchers in order to facilitate the transformation of academic innovation into novel therapeutic approa
Avanzanite Bioscience Secures €32M Series A Investment from MVM Partners18.11.2025 07:00:00 CET | Press release
MVM Partners joins as Avanzanite’s first institutional investor. Funding will scale Avanzanite’s existing infrastructure in all 32 countries in Europe, propel current launches, and support further product alliances and acquisitions. In just 3 years, Avanzanite has entered 3 strategic alliances and actively launched 3 rare disease medicines. Avanzanite’s Q3 2025 revenue tripled year-on-year and climbed over 20% quarter-on-quarter. Avanzanite is a unique, fully integrated partner for biotech and pharma innovators seeking to market and distribute their rare disease medicines in Europe. A new pan-European standard is being set for orphan medicine launches and patient access, with no one left behind. Avanzanite Bioscience B.V. (Avanzanite), a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today announced a €32 million Series A growth investment from MVM Partners (MVM), a leading global life-science private equity firm. This press release
Over 30 Million Users Benefit From Ant International’s Bettr Credit Tech Solutions18.11.2025 04:35:00 CET | Press release
Powering the Next Wave of MSME Growth with Digital Platforms in Emerging MarketsThere was a threefold year-on-year increase in eligible customers reached through partners using Bettr's credit tech solutions by the end of October 2025.The solution features an AI-driven, alternative-data-powered credit engine that can help partner platforms to cut credit policy deployment from weeks to minutes.Partnership with Dock, a leading Brazilian payments and banking technology provider, will expand the deployment of Bettr’s credit tech solutions. Bettr, a leading provider of inclusive financial services and technology business under Ant International, today announced the launch of its proprietary tailored, one-stop credit tech solutions designed to help digital platforms build and scale their lending businesses to better serve micro, small and medium enterprises (MSMEs) in emerging markets. Bettr's credit tech solutions supported over 30 million customers to gain access to credit services through
Ant International Deepens Participation in Project Ensemble as New Architecture Community Member18.11.2025 04:00:00 CET | Press release
Ant International has been a participant in the Ensemble Sandbox since 2024 Ant International today announced it has joined Project Ensemble’s Architecture Community to support the design and advancement of Hong Kong’s tokenisation ecosystem. As a Community member, it will be more involved in defining industry standards and supporting the development of Hong Kong’s tokenisation market, together with the Hong Kong Monetary Authority (HKMA) and leading peers. A fintech representative on the Community, Ant International will also contribute its technological and innovation capabilities in tokenisation to support broader industry adoption. This comes at a time when Project Ensemble reaches a new milestone with EnsembleTX, which will see it move from sandbox experiments to live market use within a pilot environment. Through EnsembleTX, Ant International will continue to broaden its partnerships with banks and other committee members, contributing to real-world use cases of tokenisation in r
Celltrion Announces European Commission Approval of Additional Line Extension for Omlyclo™ 300mg18.11.2025 03:51:00 CET | Press release
Omlyclo™ (omalizumab) is the first and only omalizumab biosimilar approved in EuropeOmlyclo™ 300 mg/2ml prefilled syringe (PFS) presentation is now approved in EU offering a simpler dosing schedule and improved patient adherence The European Commission (EC) has granted a line extension in the European Union (EU) for Celltrion’s Omlyclo™ (omalizumab), Europe’s first and only omalizumab biosimilar, for the 300 mg/2ml prefilled syringe (PFS).The European Commission (EC) approved Omlyclo™ 75 mg/0.5ml and 150mg/1ml solution for injection in pre-filled syringe in May 2024. Omlyclo™ is indicated for the treatment of patients with allergic asthma, chronic spontaneous urticaria (CSU) and chronic rhinosinusitis with nasal polyps (CRSwNP). “The additional strength of Omlyclo™ 300mg can significantly decrease the frequency of injections, and reduce injection burden and discomfort, without compromising efficacy and safety,” said Nam Lee, Vice President of Global Medical Affairs at Celltrion. “These
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom